Coherus director receives RSU and option grants
Coherus Oncology, Inc. director Mats Wahlstrom reported equity awards consisting of common stock and stock options as compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology, Inc. director Mats Wahlstrom reported equity awards consisting of common stock and stock options as compensation. He received 30,000 shares of Common Stock that constitute restricted stock units, each converting into one share upon vesting. These RSUs vest 100% on the one-year anniversary of June 3, 2026, contingent on his continued service. He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, vesting in full on June 3, 2027, also subject to continued service, and expiring on June 5, 2036. Following these awards, Wahlstrom holds 30,000 shares of Common Stock directly and 60,000 stock options.
Insider Trade Summary
Grant/Award: 90,000 shares
Grant/Award
2 txns
Insider
Wahlstrom Mats
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 30,000 shares (Direct)
Footnotes (2)
- F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Key Figures
RSU grant: 30,000 shares
Option grant size: 60,000 shares
Option exercise price: $1.45/share
+4 more
7 metrics
RSU grant
30,000 shares
Restricted stock units converting to Common Stock upon vesting
Option grant size
60,000 shares
Stock options underlying Common Stock
Option exercise price
$1.45/share
Exercise price for 60,000 stock options
RSU vesting date
One-year anniversary of June 3, 2026
100% of RSUs vest on this date
Option vesting date
June 3, 2027
All option shares vest and become exercisable
Option expiration
June 5, 2036
Expiration date of 60,000 stock options
Shares held after grant
30,000 shares
Common Stock held directly after RSU grant
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), vesting, exercise price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock and 60,000.0000 shares..."
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price of 1.4500 for the stock option grant..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The stock option grant has an expiration_date of 2036-06-05T00:00:00.000Z..."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Mats Wahlstrom acquire in the latest Coherus (CHRS) Form 4 filing?
Mats Wahlstrom received 30,000 shares of Common Stock and stock options for 60,000 shares. The awards are compensation-related, delivered as restricted stock units and options that vest over time, rather than open-market purchases or sales of Coherus Oncology stock.
How do the 30,000 Coherus (CHRS) RSUs granted to Mats Wahlstrom vest?
The 30,000 restricted stock units vest 100% on the one-year anniversary of June 3, 2026. Vesting is conditioned on Wahlstrom maintaining a service relationship with Coherus Oncology through that vesting date, aligning the grant with his continued board service.
What are the terms of the 60,000 Coherus (CHRS) stock options granted to Mats Wahlstrom?
Wahlstrom’s 60,000 stock options have an exercise price of $1.45 per share and expire on June 5, 2036. All underlying shares vest and become exercisable on June 3, 2027, assuming he continues his service relationship with Coherus through that date.
Are the Coherus (CHRS) equity grants to Mats Wahlstrom open-market transactions?
No, these are compensation-related equity awards, not open-market trades. The Form 4 shows grants of restricted stock units and stock options at no cash cost, subject to vesting conditions tied to Wahlstrom’s continued service with Coherus Oncology.
AI-generated analysis. How Rhea-AI works. Not financial advice.
